HIMS LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of Hims That A Lawsuit Has Been Filed and Urges Investors to Contact The Firm Before the August 25th Deadline

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made positive statements about its partnership with Novo, which were not supported by the actual circumstances surrounding the collaboration [4].